

Innovation and Execution Power UCB's Success

- Strong performance and upgraded 2025 guidance underpin UCB's solid growth outlook for a decade plus ahead.
- Ongoing innovation momentum —marked by KYGEVVI™ approval and strong galvokimig data— demonstrates the depth and long-term promise of UCB's pipeline.
- BIMZELX® reached over 100,000 patients worldwide, with U.S. access expanded in 2026 to include 36 million additional covered lives and commercial coverage now exceeding 80%.

Brussels, Belgium – January 13, 2026– 7:00 CET – UCB (Euronext: UCB), a global biopharmaceutical leader committed to transforming the lives of people living with severe diseases, presents at the 44th Annual J.P. Morgan Healthcare Conference its powerful growth engine, innovation-led strategy, and the expanding global impact of BIMZELX®.

Turning Strategy into Results

UCB's unwavering focus on innovation and execution excellence continues to deliver results. The company's upgraded 2025 financial guidance underscores strong momentum and resilience, supported by a portfolio of five differentiated growth drivers —BIMZELX®, RYSTIGGO®, ZILBRYSQ®, FINTEPLA®, and EVENITY®—each addressing significant unmet medical needs through unique mechanisms of action.

Jean-Christophe Tellier, CEO commented: *"Our long-dated patent protection places us in a position of strength, underpinning resilience and enabling us to navigate uncertainty with confidence and agility. At the same time, BIMZELX® continues to expand its global footprint, having reached more than 100,000 patients worldwide —a clear validation of the recognized efficacy and differentiation of the assets. This reaffirms our intact decade-plus growth trajectory, driven by the excellence of our execution and the strength of our innovation."*

Key Highlights from the Presentation

- **Financial Strength:** [Upgraded 2025 guidance](#) (on December 5th, 2025) projects revenues exceeding €7.6 billion and an adjusted EBITDA margin above 31%, positioning UCB to deliver on its Decade+ growth strategy. 2025 financial results and the 2026 financial guidance will be announced on February 26, 2026.
- **Breakthrough Innovation:** U.S. approval of KYGEVVI™, first and only approved treatment for adult and pediatric patients with Thymidine Kinase 2 deficiency, launching in Q1 2026,

reinforces UCB's commitment to addressing unmet needs. Additionally, compelling data for galvokimig in atopic dermatitis further demonstrates pipeline strength.

- **Expanded Access:** 2026 BIMZELX® coverage in the U.S. has surged, adding 36 million additional patients—a +25% increase versus 2025—bringing commercial coverage above 80%, alongside broad access for Medicaid and Medicare beneficiaries.

Confidence in Sustained Growth

With a foundation of differentiated innovation, disciplined execution, and purpose-led performance, UCB is poised to deliver long-term value for patients, shareholders, and society.

The CEO's presentation and webcast from the J.P. Morgan Healthcare Conference will be available on UCB's Investor Relations section ([Link](#)).

For further information, contact UCB:

Investor Relations

Antje Witte

T +32.2.559.94.14

email antje.witte@ucb.com

Sahar Yazdian

T +32.2.559.91.37

email <mailto:sahar.yazdian@ucb.com>

Corporate Communications

Laurent Schots

T +32.2.559.92.64

Email laurent.schots@ucb.com


About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB’s information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and



UCB News

health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

